Acute Coronary Syndromes research hub

Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study

This study is checking on people who previously took part in the IVORY trial. It's looking at whether a low dose of a medicine called IL-2 helped reduce heart problems in people who had a heart attack, by lowering inflammation in their blood vessels.

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

This study looks at a new drug, Orticumab, to see if it can reduce inflammation in the heart's arteries after a heart attack. Researchers will compare it to a dummy drug (placebo) over 6 months to see its effects.

Randomized comparison of short versus 12 months prasugrel plus aspirin in patients with acute coronary syndromes treated with percutaneous coronary intervention and everolimus-eluting stents